Evercore ISI initiated coverage of Mineralys Therapeutics (MLYS) with an Outperform rating. Following the takeout of CinCor by AstraZeneca (AZN), Mineralys has a competitor molecule for which it ran a single trial in both resistant hypertension and uncontrolled hypertension and "appears to have worked in both," the analyst tells investors. Ultimately, Evercore expects Mineralys to replicate the efficacy results in larger trials, the firm added.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MLYS:
- Mineralys Therapeutics initiated with a Buy at Stifel
- Mineralys Therapeutics presents data from Phase 2 Target-HTN trial
- Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
- Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023
- Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023